Thus while prospective trial data supporting the use of sorafenib for post-allo-HCT relapse of FLT3-ITD+ AML is lacking, there is retrospective clinical data to support its use as monotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.